Eyenovia (EYEN)
(Delayed Data from NSDQ)
$0.99 USD
0.00 (-0.04%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $0.98 -0.01 (-0.61%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Eyenovia, Inc. [EYEN]
Reports for Purchase
Showing records 1 - 20 ( 81 total )
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroPine Re-Acquisition Brings Development In-House With Optejet Expertise; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MydCombi Approval Sets Stage For Optejet; Further Mist Delivery Upside; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Boots on the Ground at AAO23-KOL Perspectives and Considerations on Therapeutic Ophthalmic Innovations
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
APP13007 Brings New Upside to Topical Ophthalmic Platform; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Optejet Goes Commercial With MydCombi-Next Progress For Presbyopia; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Announced MydCombi Approval Provides Validation For Optejet Delivery; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Making Sense of Optejet Opportunity Following MydCombi FDA Approval; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
KOL Perspective and Receptivity to MydCombi-Emphasis on May 8th PDUFA Date
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MydCombi 2Q23 PDUFA Can Set Tone for Novel Optejet Delivery; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MydCombi NDA Acceptance Paves Path For Novel Optejet Delivery
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 3 VISION-2 Trial; MydCombi NDA Resubmission Define Optejet Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 3 VISION-2 Trial Top-Line; Squinting to Read the Details
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Optejet Optimizing Delivery in Mydriasis, Presbyopia and Beyond; Initiating With Buy Rating and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Possible MydCombi Approval in 2H21; 2020 Financial Results; Raising PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
4Q20, VISION-1 Results 2Q21, MydCombi Approval 4Q21, Funded to Mid-2022
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J